Jorge Garces - Epigenomics President Chief Scientific Officer

EPGNF Stock  USD 0.50  0.00  0.00%   

President

Dr. Jorge A. Garces, Ph.D., was appointed President and Chief Scientific Officer of Epigenomics AG effective as of December 1, 2017. He will oversee Operations, Research and Development, Clinical Affairs, Regulatory and Quality at the Company. He has over 20 years of management experience in the molecular diagnostics and life sciences industries. Prior to joining Epigenomics, he served as Chief Executive Officer and President of AltheaDx Inc. and previously at Enigma Diagnostics, Inc. in the same capacity. He was also Vice President and Site Operations Manager at Hologic, Inc., where he led the development and submission to FDA for approval of their Cystic Fibrosis and HPV products. Additionally, he was a senior executive at GenMark Diagnostics and Third Wave Technologies. Earlier in his career, he held positions in clinical diagnostic laboratories including Genzyme Genetics and Athena Diagnostics. He earned his doctorate in Cell and Molecular Biology from the City University of New York. He completed his postdoctoral training in neurobiology at the University of Massachusetts Medical School and received an MBA from the Kellogg Graduate School of Management at Northwestern University. since 2017.
Age 45
Tenure 7 years
Professional MarksMBA
Phone49 30 243 450
Webhttps://www.epigenomics.com

Epigenomics Management Efficiency

The company has return on total asset (ROA) of (0.245) % which means that it has lost $0.245 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.3802) %, meaning that it generated substantial loss on money invested by shareholders. Epigenomics' management efficiency ratios could be used to measure how well Epigenomics manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 966 K in total debt with debt to equity ratio (D/E) of 0.07, which may suggest the company is not taking enough advantage from borrowing. Epigenomics AG has a current ratio of 3.8, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Epigenomics until it has trouble settling it off, either with new capital or with free cash flow. So, Epigenomics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Epigenomics AG sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Epigenomics to invest in growth at high rates of return. When we think about Epigenomics' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

PRESIDENT Age

Mark StevensonThermo Fisher Scientific
57
Dennis GibsonKroger Company
N/A
Sonya HostetlerKroger Company
N/A
Jessica AdelmanKroger Company
42
Wendy StewartIQVIA Holdings
N/A
Stephen WilliamsonThermo Fisher Scientific
57
Christine WheatleyKroger Company
53
Victor SmithKroger Company
N/A
Elizabeth OflenKroger Company
57
Dana ZurcherKroger Company
N/A
Michael McDonnellIQVIA Holdings
55
Rob KotchieIQVIA Holdings
N/A
Matthew GuginoDanaher
N/A
James ErlingerIQVIA Holdings
57
Dan RosaKroger Company
N/A
Jacob ThaysenAgilent Technologies
49
James DitkoffDanaher
67
Matthew McGrewDanaher
52
Patrick DurbinThermo Fisher Scientific
51
Colleen JuergensenKroger Company
N/A
Walter StaubIQVIA Holdings
57
Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany. Epigenomics operates under Diagnostics Research classification in the United States and is traded on OTC Exchange. It employs 36 people. Epigenomics AG [EPGNF] is a Pink Sheet which is traded through a dealer network over-the-counter (OTC).

Management Performance

Epigenomics AG Leadership Team

Elected by the shareholders, the Epigenomics' board of directors comprises two types of representatives: Epigenomics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Epigenomics. The board's role is to monitor Epigenomics' management team and ensure that shareholders' interests are well served. Epigenomics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Epigenomics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Antje Zeise, Manager Investor Relations
Guenther Reiter, Member of the Supervisory Board
Gregory Hamilton, CEO Board
Ann Kessler, Member of the Supervisory Board
Jens Ravens, CFO Board
Heino Prondzynski, Chairman of the Supervisory Board
Helge Lubenow, Member of the Supervisory Board
Thomas Taapken, CEO, CFO and Member of Executive Board
Annett Dietrich, Manager Human Resources
Noel Doheny, CEO of Epigenomics Inc.
Andrew Lukowiak, Pres Officer
Uwe Staub, COO and Member of Executive Board
Albert Weber, Sr. VP of Fin., Accounting and Controlling
Frederic Hilke, Investor Officer
Nicola HennebergBusse, Vice President - Business Development
Jorge Garces, President Chief Scientific Officer
Nicholas Potter, Director Reimbursement and Medical Affairs
Peter Vogt, Investor & Public Relations Officer

Epigenomics Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Epigenomics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with Epigenomics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Epigenomics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Epigenomics will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Epigenomics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Epigenomics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Epigenomics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Epigenomics AG to buy it.
The correlation of Epigenomics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Epigenomics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Epigenomics AG moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Epigenomics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Epigenomics AG. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.

Complementary Tools for Epigenomics Pink Sheet analysis

When running Epigenomics' price analysis, check to measure Epigenomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Epigenomics is operating at the current time. Most of Epigenomics' value examination focuses on studying past and present price action to predict the probability of Epigenomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Epigenomics' price. Additionally, you may evaluate how the addition of Epigenomics to your portfolios can decrease your overall portfolio volatility.
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Commodity Directory
Find actively traded commodities issued by global exchanges
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Please note, there is a significant difference between Epigenomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Epigenomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Epigenomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.